Quantum Genomics
Biotechnology company developing oral small‑molecule therapeutics for cardiovascular indications. Activities reported include preclinical efficacy and toxicology studies, clinical development through Phase II/III, pharmacokinetics and formulation work, regulatory interactions (including IND/FDA engagement), licensing and manufacturing partnerships, patent filings, and investor reporting.
Industries
Nr. of Employees
small (1-50)
Quantum Genomics
6 rue Cambacérès, 75008 Paris, France / 33 Rue Marbeuf, 75008 Paris, France
Patents
Compounds and compositions comprising the same for treating hypertension or heart failure
US-11345658-B2
View Details
Compounds and compositions comprising the same for treating hypertension or heart failure
US-11345658-B2
View DetailsProducts
Development‑stage oral small‑molecule cardiovascular candidate
An orally administered small‑molecule program targeting the renin‑angiotensin system with brain penetration properties, under clinical evaluation for hypertension and related cardiovascular indications.
Development‑stage oral small‑molecule cardiovascular candidate
An orally administered small‑molecule program targeting the renin‑angiotensin system with brain penetration properties, under clinical evaluation for hypertension and related cardiovascular indications.
Services
Structuring and executing licensing and collaboration agreements with regional pharmaceutical partners for development and commercialization.
End‑to‑end management of internal clinical programs including trial design, site activation, patient recruitment, regulatory interactions and data reporting.
Coordination and oversight of external manufacturing partners for clinical supply and production scale‑up, including technology transfer activities.
Organization of KOL meetings, steering committee formation and investigator engagement to support study design and recruitment.
Preparation of scientific presentations and symposia for medical conferences and organization of investigator meetings.
Structuring and executing licensing and collaboration agreements with regional pharmaceutical partners for development and commercialization.
End‑to‑end management of internal clinical programs including trial design, site activation, patient recruitment, regulatory interactions and data reporting.
Coordination and oversight of external manufacturing partners for clinical supply and production scale‑up, including technology transfer activities.
Organization of KOL meetings, steering committee formation and investigator engagement to support study design and recruitment.
Preparation of scientific presentations and symposia for medical conferences and organization of investigator meetings.
Expertise Areas
- Clinical trial management
- Cardiovascular drug development
- Small‑molecule oral formulation
- Pharmacokinetics and bioanalysis
Key Technologies
- Preclinical animal models
- Pharmacokinetic (PK) studies and bioanalysis
- Toxicology assays (genotoxicity, reproductive toxicology)
- Oral prolonged‑release tablet formulation
News & Updates
Initiation and first patient recruitment in the Phase III pivotal study for a program targeting difficult‑to‑treat hypertension.
Report of a positive response from the FDA regarding the Phase III development plan and protocols.
Regulatory agreement from the US authority to launch the Phase II NEW‑HOPE study in the United States.
Publication of positive results from a Phase IIa study for a development candidate in hypertension.
Announcement of recruitment of first patients in the NEW‑HOPE Phase II study in the United States.
Announcement of a strategic manufacturing agreement with a contract manufacturer to support production and clinical supply.
Initiation and first patient recruitment in the Phase III pivotal study for a program targeting difficult‑to‑treat hypertension.
Report of a positive response from the FDA regarding the Phase III development plan and protocols.
Regulatory agreement from the US authority to launch the Phase II NEW‑HOPE study in the United States.
Publication of positive results from a Phase IIa study for a development candidate in hypertension.
Announcement of recruitment of first patients in the NEW‑HOPE Phase II study in the United States.
Announcement of a strategic manufacturing agreement with a contract manufacturer to support production and clinical supply.